Andrew Epstein
General Practice · Tucson, AZNPI 1902141930
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $224,079 of the $224,641 with a category attached, or 99.7%. CSL Behring accounts for 70.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $69,375 and has fallen 97.1% since, to $2,018 in 2024. Among general practice clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $1170.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$159K
- CSL Plasma Inc.$59K
- Abbott$7K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$353
- Genentech USA, Inc.$90
- Medtronic$32
- plus $86 from 5 others
What the payments were for
- Consulting fees$224,079100%
- Food & beverage$5620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 129 | $158,742 |
| CSL Plasma Inc. | 34 | $58,813 |
| Abbott | 15 | $6,525 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $353 |
| Genentech USA, Inc. | 4 | $90 |
| Medtronic | 2 | $32 |
| AbbVie | 1 | $23 |
| Pfizer | 1 | $20 |
| DUSA Pharmaceuticals, Inc. | 1 | $19 |
| EPI Health, LLC | 1 | $14 |
| Merz North America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optisure Defibrillation ICD Lead$6,525
- ALTRENO$156
- BRYHALI$156
- SILIQ$106
How this compares
$224,641 in reported general payments places this provider in the 95th percentile of 1,998 general practice providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $17,982 |
| XareltoRivaroxaban | 26 | $14,404 |
| Midodrine Hcl | 19 | $4,797 |
| Quetiapine Fumarate | 121 | $3,208 |
| Gabapentin | 71 | $1,839 |
| Amlodipine Besylate | 71 | $1,015 |
| Mirtazapine | 42 | $997 |
| Sertraline Hcl | 52 | $942 |
| Trazodone Hcl | 58 | $873 |
| Omeprazole | 45 | $857 |
| Lisinopril | 53 | $819 |
| Famotidine | 39 | $747 |
| Losartan Potassium | 24 | $736 |
| Pantoprazole Sodium | 35 | $720 |
| Atorvastatin Calcium | 41 | $680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $17,98230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,998 general practice providers in Arizona.
Other general practice in Tucson
- Alexander CadouxTucson$61K
- Adam PershingTucson$11K
- Shazim FayyazTucson$11K
- Kevin SchmidtkeTucson$9K
- Curtis HamannPhoenix$1.9M
- Mehrdad MehranfarPhoenix$967K
- Trent SmallwoodTempe$481K
- Taylor KimApache Junction$389K
- Enrico DivitoScottsdale$289K
- John YuOro Valley$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.